Skip to main content

Table 3 Comparison of the effect of rivaroxaban (CTR) measured in 3 trough and 3 peak samples

From: Clot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with Rivaroxaban

 

Trough 1

Trough 2

Trough 3

ANOVA P

Average

CV (%)

Peak 1

Peak 2

Peak 3

ANOVA P

Average CV (%)

Rivaroxaban 20

          

N

Median

Min-max

29

1.34

1.08–3.36

30

1.32

0.94–1.81

30

1.34

1.01–1.67

0.029*

30

4.8

0.72–40.7

29

3.77

1.96–6.2

30

3.71

2.10–5.88

30

3.69

1.89–5.49

0.297

30

9.4

1.89–24.9

Rivaroxaban 15

          

N

Median

Min-max

30

1.32

1.02–2.53

30

1.30

1.03–2.78

29

1.37

0.93–3.23

0.914

30

4.61

1.61–24.7

30

3.53

2.08–6.58

30

3.27

1.89–6.17

28

3.14

1.80–7.03

0.303

30

8.34

0.56–28.1

  1. Number of samples (N), median and range (min-max) are presented for each sampling, and the average coefficient of variation (CV) between them are shown. Result from repeated measure analysis is presented with ANOVA P.